Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

Míreanna comhchosúla

• Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
  de réir: Amir T. Fathi (15313195)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  de réir: Srivandana Akshintala (16610490)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  de réir: Srivandana Akshintala (16610490)
  Foilsithe / Cruthaithe: (2025)
• Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
  de réir: Evan C. Chen (15054014)
  Foilsithe / Cruthaithe: (2025)
• Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
  de réir: Evan C. Chen (15054014)
  Foilsithe / Cruthaithe: (2025)